Vaccine
Talk
(Egyptian Edition)
"Everything you need to know about
vaccines in Egypt"
Vaccine
← Special PopulationsHCP · Special populations
Corticosteroids and immunosuppressive drugs
Immunosuppressive medication profiles (AAAAI) and universal vaccine timing windows (CDC, IDSA, Australian Immunisation Handbook) — organized for clinical reference.
Immunosuppressive medications & vaccination guidelines
Managing vaccines during immunosuppressive therapy requires balancing infection prevention with medical safety. This guide is organized in two core parts:
- Part 1 — Immunosuppressive drug reference: mechanisms, indications, and monitoring warnings based on AAAAI data.
- Part 2 — Universal vaccine timing matrix: safe vaccination windows before, during, and after therapy based on CDC, IDSA, and Australian Immunisation Handbook consensus.
Use these tables alongside individual patient factors — including diagnosis, dose, duration, concurrent therapies, and laboratory immune markers — when planning immunization.
Part 1: Comprehensive immunosuppressive drug database
Reference tables below outline targets, therapeutic uses, and key monitoring warnings for medications commonly prescribed across autoimmune, autoinflammatory, transplant, and oncologic conditions.
Traditional & oral immunosuppressives
Table 1. Corticosteroids, antimetabolites, and conventional DMARDs
| Medication & examples | Target & mechanism | Indications for use | Monitoring & cautions |
|---|---|---|---|
| Corticosteroids (Prednisone, methylprednisolone, dexamethasone) | Broad anti-inflammatory. Stops cytokine production, depletes T cells, B cells, and eosinophils, and restricts immune cell migration to injury sites. | Autoimmune diseases, asthma, urticaria (hives). | Long-term use risks: bone health issues, hypertension, blood sugar shifts, cataracts, and infections (including rare pneumonia). Consult before vaccinations. |
| Colchicine | Neutrophil function. Reduces neutrophil activity to lower localized inflammation. | Gout flares, Familial Mediterranean Fever (FMF), other autoinflammatory disorders. | Diarrhea, nausea, vomiting. Risk of liver, kidney, muscle damage, or cytopenias. Highly drug-interactive. Avoid grapefruit juice. |
| Hydroxychloroquine (Plaquenil) | Immune cell signaling. Lowers general inflammatory response; may block dendritic cell activation. | Lupus, rheumatoid arthritis, malaria, chronic urticaria. | GI upset, rash, vision changes, cytopenias. Not associated with increased infection risk. Requires regular eye exams. |
| Sulfasalazine | Prostaglandin formation. Active component (5-aminosalicylate) gradually reduces inflammation. | Rheumatoid arthritis, juvenile RA, psoriatic arthritis, ulcerative colitis. | Nausea, headache, sun sensitivity, rash, orange urine, temporary low sperm count. Avoid if sulfa- or salicylate-allergic; caution in G6PD deficiency. Monitor blood counts. |
| Dapsone | Bacterial folate synthesis. Prevents free radical cell injury and inhibits leukotrienes/prostaglandins. | Leprosy/infections, dermatitis herpetiformis, other autoimmune conditions. | GI upset, rash, headache. Less common: mood changes, cytopenias, liver/kidney damage, male infertility. Avoid if sulfa-allergic; caution in G6PD deficiency. |
| Methotrexate | Folic acid utilization. Blocks folic acid use, halting DNA/RNA generation needed for T- and B-cell growth. | Rheumatoid arthritis, autoimmune diseases, certain cancers. | Higher bacterial/viral infection risk. Screen for hepatitis B/C; routine liver/kidney tests. Folic acid often co-prescribed to reduce toxicity. |
| Mycophenolate mofetil (CellCept, Myfortic) | IMPDH enzyme. Blocks IMPDH required for DNA/RNA synthesis in T and B cells. | Autoimmune diseases, solid organ transplant rejection prevention. | Higher bacterial/viral infection risk. Screen for hepatitis B/C; ongoing blood/liver/kidney monitoring. Avoid live vaccines. |
| Azathioprine (Imuran) | DNA synthesis. Mimics DNA components to disrupt synthesis, slowing T- and B-cell division. | Autoimmune diseases, transplant rejection prevention. | Increased viral/bacterial infection risk. Hepatitis B/C screening; TPMT testing may precede therapy. Monitor blood/liver/kidney. May increase malignancy risk. |
Innate Immunity Targets (Biologics & Small Molecules)
Table 2. Anti-cytokine biologics and oral JAK inhibitors
| Medication & examples | Target & mechanism | Indications for use | Monitoring & cautions |
|---|---|---|---|
| Anti-IL-1 biologics (Anakinra/Kineret, Canakinumab/Ilaris, Rilonacept/Arcalyst) | Interleukin-1 (IL-1). Blocks IL-1 to suppress early fever and joint/tissue inflammation. | CAPS (including FCAS, Muckle-Wells), systemic juvenile idiopathic arthritis, rheumatoid arthritis. | Injection site reactions, serious bacterial infections, cytopenias. |
| Anti-TNF biologics (Etanercept/Enbrel, Infliximab/Remicade, Adalimumab/Humira, Certolizumab/Cimzia, Golimumab/Simponi) | Tumor necrosis factor (TNF). Blocks TNF to stop downstream inflammation in joints, skin, and gut. | RA, psoriasis, psoriatic arthritis, IBD (Crohn's, UC), ankylosing spondylitis. | Serious bacterial, fungal, and viral infections (especially TB reactivation). Screen for TB and hepatitis B/C before starting. |
| Anti-IL-6 biologics (Tocilizumab/Actemra, Sarilumab/Kevzara) | Interleukin-6 (IL-6). Blocks IL-6 to halt systemic inflammation and acute-phase responses. | RA, giant cell arteritis, systemic/polyarticular JIA, cytokine release syndrome (CRS). | Upper respiratory infections, leukopenia, thrombocytopenia, elevated liver enzymes, hyperlipidemia. Rare bowel perforation. |
| Complement inhibitor (Eculizumab/Soliris) | Complement C5. Prevents uncontrolled complement activation in the innate immune cascade that destroys host cells in PNH and aHUS. | Paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS). | Markedly increased Neisseria infection risk (including meningococcus). Meningococcal vaccination required before starting; antibiotic prophylaxis during therapy. |
| JAK inhibitors (Tofacitinib/Xeljanz, Upadacitinib/Rinvoq, Baricitinib/Olumiant) | Janus kinase (JAK) pathways. Oral small molecules blocking intracellular inflammatory cytokine signaling. | RA, psoriatic arthritis, ulcerative colitis, atopic dermatitis, alopecia areata. | Serious infections (notably shingles, TB, fungal). Cytopenias, elevated lipids, thrombosis, major cardiac events, and malignancy risk. |
B-cell depletion & selective biologics
Table 3. B-cell depletion & selective biologics
| Medication & examples | Target & mechanism | Indications for use | Monitoring & cautions |
|---|---|---|---|
| Anti-CD20 biologics (Rituximab/Rituxan, Ocrelizumab/Ocrevus, Ofatumumab/Kesimpta) | CD20 on B cells. Depletes B cells from circulation, preventing autoantibody production. | RA, ANCA vasculitis, pemphigus vulgaris, multiple sclerosis, certain lymphomas. | Viral reactivation (hepatitis B, shingles). Hypogammaglobulinemia over time. Infusion reactions common with first dose. |
| Belimumab (Benlysta) | BLyS/BAFF protein. Prevents B-cell activating factor binding, causing abnormal B cells to undergo apoptosis. | Systemic lupus erythematosus (SLE), lupus nephritis. | Infusion/injection reactions, GI upset, mood changes. Infection risk increased but generally less than broad B-cell depleters. |
| Abatacept (Orencia) | T-cell co-stimulation. Binds CD80/CD86 on antigen-presenting cells, blocking T-cell activation signals. | Rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis. | Infections (especially upper respiratory). Do not combine with anti-TNF biologics (extreme infection risk). TB/hepatitis screening required. |
| Anti-IL-17 biologics (Secukinumab/Cosentyx, Ixekizumab/Taltz, Brodalumab/Siliq) | Interleukin-17 (IL-17). Blocks IL-17 to reduce skin and joint tissue inflammation. | Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis. | Localized fungal infections (e.g., oral thrush). May trigger or worsen IBD. Mild upper respiratory infections. |
| Anti-IL-12 / IL-23 biologics (Ustekinumab/Stelara, Risankizumab/Skyrizi, Guselkumab/Tremfya) | Interleukin-12 and/or IL-23. Blocks cytokines that drive overactive T-cell pathways in skin and gut. | Plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis. | Generally well tolerated. Upper respiratory infections, headache, injection-site fatigue. TB screening before initiation. |
Core concepts: live vs non-live vaccines
Before using the timing matrix, distinguish the two vaccine categories:
Live-attenuated vaccines
Examples: MMR, varicella, yellow fever, oral rotavirus. Contain weakened but replicating organisms. During significant immunosuppression the host may fail to control the vaccine strain, risking severe vaccine-derived infection. Generally contraindicated during active immunosuppression.
Non-live / inactivated vaccines
Examples: inactivated influenza, COVID-19, Shingrix, pneumococcal, Tdap. Cannot replicate or cause infection — physically safe at any time. Immunosuppression may still blunt antibody responses, so timing optimization remains clinically important.
Part 2: Unified vaccine timing matrix
Master reference merging AAAAI drug-risk profiles with CDC and Australian Immunisation Handbook vaccine scheduling guidance. Columns define pre-treatment windows, status during active therapy, and post-therapy recovery intervals before live vaccines may resume.
Table 4. Immunosuppressive risk tiers and vaccine timing windows
| Therapeutic category / condition | Risk tier | Target / mechanism | Before treatment | During active therapy | After treatment / recovery |
|---|---|---|---|---|---|
| High-dose corticosteroids • Prednisone ≥20 mg/day (or ≥2 mg/kg/day if <10 kg) for >14 days | Severe | Broadly halts cytokine production, depletes circulating lymphocytes, and prevents cell migration. | Live: ≥4 weeks prior Non-live: ≥2 weeks prior | Live: CONTRAINDICATED Non-live: Safe, but antibody response is blunted | Wait ≥4 weeks (1 month) after stopping before live vaccines |
| Low-dose traditional DMARDs • Methotrexate (≤25 mg/week) • Azathioprine (≤3 mg/kg/day) • Mercaptopurine (≤1.5 mg/kg/day) | Mild | Inhibits purine, pyrimidine, or folate metabolism to slow overactive T- and B-cell division. | No special wait. Baseline schedules apply. | Live: CONTRAINDICATED Non-live: Safe. Consider pausing methotrexate 2 weeks post–influenza vaccine to improve antibody yield. | Wait 1–3 months after stopping before live vaccines |
| High-dose / oncological DMARDs • Methotrexate (>25 mg/week) • Azathioprine (>3 mg/kg/day) • Mercaptopurine (>1.5 mg/kg/day) | Moderate to severe | Induces deeper cell-cycle arrest and lymphocyte depletion than low-dose regimens. | Live: ≥4 weeks prior Non-live: ≥2 weeks prior | Live: CONTRAINDICATED Non-live: Safe, but protection levels are reduced | Wait 3 months after discontinuing before live vaccines |
| Mycophenolate mofetil (CellCept, Myfortic) | Severe | Blocks IMPDH enzyme required for DNA/RNA synthesis in growing T and B cells. | Live: ≥4 weeks prior Non-live: ≥2 weeks prior | Live: CONTRAINDICATED Non-live: Safe, but antibody response is heavily blunted | Wait 3 months after discontinuing before live vaccines |
| Calcineurin & mTOR inhibitors • Ciclosporin & tacrolimus • Sirolimus & everolimus | Tiered: mild (autoimmune) → severe (transplant) | Inhibits IL-2 or mTOR pathways to block T-cell activation. | Live: ≥4 weeks prior Non-live: ≥2 weeks prior | Live: CONTRAINDICATED Non-live: Safe, but protection compromised at severe/transplant doses | ≥3 months if autoimmune use; ≥12 months if used for solid organ transplant rejection |
| Alkylating agents • Cyclophosphamide | Severe | Cross-links DNA strands, triggering growth arrest and deep lymphocyte depletion. | Live: ≥4 weeks prior Non-live: ≥2 weeks prior | Live: CONTRAINDICATED Non-live: Safe, but response is minimized | Wait 3 months after stopping before live vaccines |
| Cytotoxic cancer chemotherapy | Severe | Non-selectively halts cellular replication, damaging active white blood cell pools. | Live: ≥4 weeks prior Non-live: ≥2 weeks prior | Live: CONTRAINDICATED Non-live: Safe, but antibody responses are extremely blunted | Wait 3–12 months post-chemotherapy (depends on CD4+ T-cell recovery) |
| JAK inhibitors (oral) • Tofacitinib, upadacitinib, baricitinib | Moderate | Blocks JAK pathways intracellularly, disrupting downstream cytokine signals. | Live: ≥4 weeks prior Non-live: ≥2 weeks prior | Live: CONTRAINDICATED Non-live: Safe, but response may be suboptimal | Wait 1–3 months after stopping, based on drug half-life |
| Oncological kinase inhibitors • BTK inhibitors (e.g., ibrutinib) • ALK & CDK4/6 inhibitors | Tiered: moderate (BTK) / mild (ALK/CDK4/6) | BTK inhibitors reduce B-cell survival; ALK/CDK4/6 agents halt malignant cell cycles. | Live: ≥4 weeks prior Non-live: ≥2 weeks prior | Live: CONTRAINDICATED Non-live: Safe to administer | Wait 3 months after completing regimens; unlikely immunosuppressive after clearance |
| B-cell depleting biologics • Rituximab, ocrelizumab, ofatumumab | Severe | Targets and depletes CD20+ mature B cells, halting autoantibody production. | Live: ≥4 weeks prior Non-live: ≥2–4 weeks prior | Live: CONTRAINDICATED Non-live: Safe, but minimal to no new antibody generation | Live: contraindicated during and <6 months post-treatment Non-live: give 5–6 months after last infusion (or ≥4 weeks before next dose) |
| Anti-TNF & cytokine biologics • Anti-TNF (Humira, Remicade) • Anti-IL-6 (Actemra, sarilumab) | Moderate | Neutralizes inflammatory proteins (TNF or IL-6) to halt systemic tissue damage. | Live: ≥4 weeks prior Non-live: ≥2 weeks prior | Live: CONTRAINDICATED Non-live: Safe; often yields effective antibody levels | Wait 3 months (or 1–2 half-lives) after stopping before live vaccines |
| Selective cytokine biologics • Anti-IL-17 (secukinumab) • Anti-IL-12/23 (ustekinumab) | Mild | Targeted interleukin blockade in skin and gut inflammatory pathways. | Live: ≥4 weeks prior Non-live: ≥2 weeks prior | Live: CONTRAINDICATED Non-live: Safe; reliable protective responses | Wait 3 months after stopping before live vaccines |
| T-cell co-stimulation blockers • Abatacept (Orencia) | Severe | Binds CD80/CD86 to block secondary T-cell activation signals. | Live: ≥4 weeks prior Non-live: ≥2 weeks prior | Live: CONTRAINDICATED Non-live: Safe, but antibody generation is heavily blunted | Wait ≥3 months after stopping before live vaccines |
| Advanced cellular therapies • CAR-T cell therapy • Stem cell transplants (HSCT) | Severe | Complete lymphodepletion via engineered cells or myeloablative conditioning. | Defer all scheduling to oncology teams | Live: STRICTLY CONTRAINDICATED Non-live: Defer | Defer live and non-live vaccines 6–24 months post-transplant; full re-immunization required |
| Mild immunomodulators • Hydroxychloroquine, sulfasalazine | None / mild | Mild lysosomal modulation without structural immune gaps. | No special wait. Baseline schedules apply. | Live: SAFE Non-live: SAFE — full vaccine efficacy expected | No delays or post-treatment wait required |
| Non-immunosuppressive biologics • Anti-CGRP (fremanezumab) • Anti-RANKL (denosumab) • Anti-IgE (omalizumab) | None | Blocks non-immune pathways (migraine, bone turnover, mast cell IgE). | No special wait. Baseline schedules apply. | Live: SAFE Non-live: SAFE — full vaccine efficacy expected | No delays required |
| Primary inborn errors of immunity • SCID, complete DiGeorge syndrome | Severe | Genetic defects causing absent or non-functional T- and B-cell lines. | N/A (lifelong condition) | Live: STRICTLY CONTRAINDICATED Non-live: Safe, but requires specialist management | Permanent live vaccine contraindication unless corrected by successful stem cell or thymic transplant |
| HIV / AIDS • CD4+ <200 cells/μL • CD4+ 200–499 cells/μL • CD4+ ≥500 cells/μL | Tiered: severe (<200) → moderate (200–499) → mild (≥500) | Retroviral destruction of helper CD4+ T lymphocytes. | N/A (lifelong condition) | Live: contraindicated in severe/moderate tiers; safe in mild tier Non-live: safe and recommended at all tiers | Live vaccines contraindicated until ART restores CD4+ to ≥500 cells/μL |
| Active hematological malignancies • Leukemia, lymphoma, myeloma | Severe | Malignant lines proliferate in marrow, crowding out normal immune cells. | Live: ≥4 weeks prior Non-live: ≥2 weeks prior | Live: STRICTLY CONTRAINDICATED Non-live: Safe, but protection is minimal | Live vaccines contraindicated until verified long-term remission |
| End-stage organ failure • CKD (eGFR <15) • Advanced liver cirrhosis | Moderate | Uremia or hepatic failure causes functional phagocyte defects. | Complete vaccines early during organ failure decline | Live: high caution; often deferred if transplant imminent Non-live: safe and recommended | Risk shifts to severe immediately upon transplant and anti-rejection therapy |
Clinical alert: in-utero biologic exposure
Pregnancy exposure: Highly immunosuppressive biologics — especially anti-TNF agents (e.g., adalimumab/Humira) and anti-CD20 agents (e.g., rituximab) — readily cross the placenta in the second and third trimesters.
Infant live-vaccine safety: Exposed infants must not receive live-attenuated vaccines (notably BCG and oral rotavirus) until at least 6 months of age, allowing clearance of maternal drug. Standard non-live childhood vaccines should follow routine pediatric schedules.
Protecting the household: cocooning strategy
When live vaccines are unsafe for the immunocompromised patient, household members, partners, and close contacts should remain fully vaccinated against measles, varicella, influenza, and other preventable diseases.
This cocooning approach creates a protective barrier around the patient and substantially reduces the probability of household introduction of vaccine-preventable viruses.
References & clinical guidelines
To ensure maximum safety and data transparency for our users, all medical timelines, drug risk tiers, and vaccine windows on this page are compiled from global medical authorities:
- Drug profiles & biological mechanisms: American Academy of Allergy, Asthma & Immunology (AAAAI) — Immunosuppressive Medication for the Treatment of Autoimmune Disease Guide.
- Universal vaccine scheduling guidelines: Centers for Disease Control and Prevention (CDC) — General Best Practice Guidelines for Immunization: Altered Immunocompetence.
- Immunocompromise levels & drug potentials: The Australian Immunisation Handbook — Guidance on Secondary Immunodeficiencies Due to Medical Conditions and Therapies (Tables for Corticosteroids, Conventional, Biological, and Small Molecule Therapies).